Search
Sotorasib
go.drugbank.com/drugs/DB15569ApprovedInvestigational[L34288] This mutation makes up >50% of all KRAS mutations.[A187550] Mutant KRAS discovered in 1982 but was not considered a druggable target until the mid-2010s.
Fluoroestradiol F-18
go.drugbank.com/drugs/DB15690ApprovedInvestigationalacross metastases (i.e. to identify sites that no longer express ER) without the need for multiple biopsies. … [L14096] The ability to image ER-positive tumors _in vivo_ is advantageous in that, while helping to visualize tumor progression/regression, it may also be used to assess for heterogeneity in ER expression
Ioxaglic acid
go.drugbank.com/drugs/DB09313ApprovedWithdrawnIoxaglic acid is marketed as Hexabrix. This drug is an ionic tri-iodinated benzoate used as a low-osmolality contrast agent during diagnostic imaging procedures. Like other organic iodine compounds, ioxaglic acid blocks x-rays and is opa...
Categories: Compounds used in a research, industrial, or household settingRubidium Rb-82
go.drugbank.com/drugs/DB09479ApprovedInvestigationalIt is indicated for Positron Emission Tomography (PET) imaging of the myocardium under rest or pharmacologic stress conditions to evaluate regional myocardial perfusion in adult patients with suspected … or existing coronary artery disease.
Flutemetamol (18F)
go.drugbank.com/drugs/DB09151ApprovedInvestigationalFlutemetamol (18F), an analogue of [(11)C]PIB,[A18519] is a radioactive diagnostic drug used for Positron Emission Tomography (PET) imaging of the brain to estimate β amyloid neuritic plaque density. … It is used to evaluate Alzheimer's disease (AD) or other causes of cognitive decline as an Aβ-specific positron emission tomography (PET) ligand.[L35029]
Categories: Compounds used in a research, industrial, or household settingOpicapone
go.drugbank.com/drugs/DB11632ApprovedInvestigational[L2336] Opicapone is used for adjunct therapy to levodopa and carbidopa in adult patients with Parkinson's disease and end-of-dose motor fluctuations. … Opicapone was approved for use by the European Commission in June 2016 [L2339] and the FDA in April 2020.[L13772] It is marketed under the brand name Ongentys as once-daily oral capsules.
Ethambutol
go.drugbank.com/drugs/DB00330ApprovedInvestigational[A229048] It was developed out of a need for therapies active against isoniazid resistant strains of _Mycobacterium tuberculosis_.[A229048] Ethambutol was granted FDA approval on 6 November 1967.
Categories: Antiinfectives for Systemic Use, Drugs for Treatment of TuberculosisDemeclocycline
go.drugbank.com/drugs/DB00618ApprovedBecause it is excreted more slowly than tetracycline, it maintains effective blood levels for longer periods of time.
Categories: Antibiotics for Topical Use, Antibacterials for Systemic UseVimseltinib
go.drugbank.com/drugs/DB17520ApprovedInvestigational[L52230,A265035] Vimseltinib - under the brand name Romvimza - was approved by the FDA in February 2025 for the treatment of tenosynovial giant cell tumours for which surgical resection is not appropriate … [L52230] It is highly selective, with a >500-fold selectivity for CSF1R over its nearest off-target kinase.
Belinostat
go.drugbank.com/drugs/DB05015ApprovedInvestigationalThe safety and efficacy of belinostat is currently being evaluated for use in combination with traditional front-line therapies for the treatment of PTCL. … It was US-approved in July 2014 as a therapeutic agent for relapsed or refractory peripheral T-cell lymphoma.